The PKC inhibitor AEB071 may be a therapeutic option for psoriasis

Journal of Clinical Investigation

Volumn 118, Issue 9, 2008, Pages 3151-3159

  Skvara, Hans ^a   Dawid, Markus ^a   Kleyn, Elise ^b   Wolff, Barbara ^c   Meingassner, Josef G ^c   Knight, Hilary ^d   Dumortier, Thomas ^d   Kopp, Tamara ^a   Fallahi, Nasanin ^a   Stary, Georg ^a   Burkhart, Christoph ^d   Grenet, Olivier ^d   Wagner, Juergen ^d   Hijazi, Youssef ^d   Morris, Randall E ^d   McGeown, Claire ^d   Rordorf, Christiane ^d   Griffiths, Christopher E M ^b   Stingl, Georg ^a   Jung, Thomas ^d  

^a Universitatsklinik fur Dermatologie   (Austria)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Institute for Biomedical Ingineering   (Austria)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AEB 071; CYTOKINE; MESSENGER RNA; PLACEBO; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EX VIVO STUDY; EXPERIMENTAL RAT; HALF LIFE TIME; HEADACHE; HEART RATE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; KERATINOCYTE; KIDNEY FUNCTION; LYMPHOCYTE ACTIVATION; MACROPHAGE; MULTICENTER STUDY; NAUSEA; NIGHT SWEAT; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PULSE RATE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RAT; SCORING SYSTEM; SIDE EFFECT; SKIN ALLERGY; SKIN CELL; SKIN DEFECT; T LYMPHOCYTE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; DERMATITIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; HYPERSENSITIVITY; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; PLACEBOS; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; PSORIASIS; RATS; SKIN;

EID: 51349152055     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI35636     Document Type: Article

References (46)

1. Newton, A.C. 2003. Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem. J. 370:361-371.
2. Spitaler, M., and Cantrell, D.A. 2004. Protein kinase C and beyond. Nat. Immunol. 5:785-790.
3. Guo, B., Su, T.T., and Rawlings, D.J. 2004. Protein kinase C family functions in B-cell activation. Curr. Opin. Immunol. 16:367-373.
4. Mecklenbrauker, I., Saijo, K., Zheng, N.Y., Leitges, M., and Tarakhovsky, A. 2002. Protein kinase Cdelta controls self-antigen-induced B-cell tolerance. Nature. 416:860-865.
5. Monks, C.R., Kupfer, H., Tamir, I., Barlow, A., and Kupfer, A. 1997. Selective modulation of protein kinase C-theta during T-cell activation. Nature. 385:83-86.
6. Bauer, B., et al. 2000. T cell expressed PKCtheta demonstrates cell-type selective function. Eur. J. Immunol. 30:3645-3654.
7. Manicassamy, S., Gupta, S., and Sun, Z. 2006. Selective function of PKC-theta in T cells. Cell Mol. Immunol. 3:263-270.
8. Tan, S.L., et al. 2006. Resistance to experimental autoimmune encephalomyelitis and impaired IL-17 production in protein kinase C theta-deficient mice. J. Immunol. 176:2872-2879.
9. -/- mice. J. Immunol. 176:6004-6011.
10. Chaudhary, D., and Kasaian, M. 2006. PKCtheta: A potential therapeutic target for T-cell-mediated diseases. Curr. Opin. Investig. Drugs. 7:432-437.
11. Griffiths, C.E., and Barker, J.N. 2007. Pathogenesis and clinical features of psoriasis. Lancet. 370:263-271.
12. Lowes, M.A., Bowcock, A.M., and Krueger, J.G. 2007. Pathogenesis and therapy of psoriasis. Nature. 445:866-873.
13. Nickoloff, B.J., and Nestle, F.O. 2004. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. 113:1664-1675.
14. Breitkreutz, D., et al. 2007. Protein kinase C family: On the crossroads of cell signaling in skin and tumor epithelium. J. Cancer Res. Clin. Oncol. 133:793-808.
15. Xia, Y.P., et al. 2003. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood. 102:161-168.
16. Sano, S., et al. 2005. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 11:43-49.
17. Fredriksson, T., and Pettersson, U. 1978. Severe psoriasis - oral therapy with a new retinoid. Dermatologica. 157:238-244.
18. Gordon, K.B., Bonish, B.K., Patel, T., Leonardi, C.L., and Nickoloff, B.J. 2005. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br. J. Dermatol. 153:945-953.
19. Clarke, M., and Dodson, P.M. 2007. PKC inhibition and diabetic microvascular complications. Best Pract. Res. Clin. Endocrinol. Metab. 21:573-586.
20. Herbst, R.S., Oh, Y., Wagle, A., and Lahn, M. 2007. Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer. Clin. Cancer Res. 13:s4641-s4646.
21. Serova, M., et al. 2006. Preclinical and clinical development of novel agents that target the protein kinase C family. Semin. Oncol. 33:466-478.
22. Haider, A.S., et al. 2008. Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J. Immunol. 180:1913-1920.
23. Lowes, M.A., et al. 2008. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest Dermatol. 128:1207-1211.
24. Teunissen, M.B., Koomen, C.W., de Waal, M.R., Wierenga, E.A., and Bos, J.D. 1998. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J. Invest. Dermatol. 111:645-649.
25. Zheng, Y., et al. 2007. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 445:648-651.
26. Gottlieb, S.L., et al. 1995. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. 1:442-447.
27. Krueger, J.G., et al. 2000. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J. Am. Acad. Dermatol. 43:448-458.
28. Abrams, J.R., et al. 1999. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103:1243-1252.
29. Ellis, C.N., and Krueger, G.G. 2001. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. 345:248-255.
30. Weinshenker, B.G., Bass, B.H., Ebers, G.C., and Rice, G.P. 1989. Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. J. Am. Acad. Dermatol. 20:1132-1133.
31. Utset, T.O., et al. 2002. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J. Rheumatol. 29:1907-1913.
32. Chaudhari, U., et al. 2001. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 357:1842-1847.
33. Kauffman, C.L., et al. 2004. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123:1037- 1044.
34. Kleyn, C.E., and Griffiths, C.E. 2006. Infliximab for the treatment of psoriasis. Expert. Opin. Biol. Ther. 6:797-805.
35. Philipp, S., et al. 2006. The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder. Expert. Opin. Ther. Targets. 10:817-831.
36. Nestle, F.O., and Conrad, C. 2004. The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis. J. Invest. Dermatol. 123:xiv-xxv.
37. Lee, E., et al. 2004. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 199:125-130.
38. Nagpal, S., Lu, J., and Boehm, M.F. 2001. Vitamin D analogs: mechanism of action and therapeutic applications. Curr. Med. Chem. 8:1661-1679.
39. Johnson, A., and Chandraratna, R.A. 1999. Novel retinoids with receptor selectivity and functional selectivity. Br. J. Dermatol. 140(Suppl. 54):12-17.
40. Detmar, M., et al. 1994. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J. Exp. Med. 180:1141-1146.
41. Aziz, M.H., Manoharan, H.T., and Verma, A.K. 2007. Protein kinase C epsilon, which sensitizes skin to sun's UV radiation-induced cutaneous damage and development of squamous cell carcinomas, associates with Stat3. Cancer Res. 67:1385-1394.
42. Cataisson, C., Pearson, A.J., Torgerson, S., Nedospasov, S.A., and Yuspa, S.H. 2005. Protein kinase C alpha-mediated chemotaxis of neutrophils requires NF-kappa B activity but is independent of TNF alpha signaling in mouse skin in vivo. J. Immunol. 174:1686-1692.
43. Cataisson, C., et al. 2003. Activation of cutaneous protein kinase C alpha induces keratinocyte apoptosis and intraepidermal inflammation by independent signaling pathways. J. Immunol. 171:2703-2713.
44. Cataisson, C., et al. 2006. CXCR2 ligands and G-CSF mediate PKCalpha-induced intraepidermal inflammation. J. Clin. Invest. 116:2757-2766.
45. Boyman, O., et al. 2004. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J. Exp. Med. 199:731-736.
46. Bangert, C., Friedl, J., Stary, G., Stingl, G., and Kopp, T. 2003. Immunopathologic features of allergic contact dermatitis in humans: participation of plasmacytoid dendritic cells in the pathogenesis of the disease? J. Invest. Dermatol. 121:1409-1418.